Sickle Cell Anemia Testing and Screening

Global Sickle Cell Anemia Testing and Screening Market to Reach US$715.4 Million by 2030

The global market for Sickle Cell Anemia Testing and Screening estimated at US$413.0 Million in the year 2024, is expected to reach US$715.4 Million by 2030, growing at a CAGR of 9.6% over the analysis period 2024-2030. Hemoglobin, one of the segments analyzed in the report, is expected to record a 9.2% CAGR and reach US$338.3 Million by the end of the analysis period. Growth in the High-Performance Liquid Chromatography segment is estimated at 8.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$112.5 Million While China is Forecast to Grow at 13.0% CAGR

The Sickle Cell Anemia Testing and Screening market in the U.S. is estimated at US$112.5 Million in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$144.8 Million by the year 2030 trailing a CAGR of 13.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 6.9% and 8.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 7.5% CAGR.

Global Sickle Cell Anemia Testing and Screening Market – Key Trends & Drivers Summarized

Why Is Sickle Cell Anemia Testing Becoming a Global Healthcare Priority? Understanding the Rising Demand for Early Diagnosis

Sickle cell anemia testing and screening have gained increasing importance as governments and healthcare institutions prioritize early detection and disease management. Sickle cell disease (SCD) is a genetic blood disorder that affects millions worldwide, particularly in regions with high prevalence rates, such as Africa, the Middle East, India, and parts of North and South America. Early diagnosis is crucial in preventing complications such as stroke, organ damage, and severe pain crises. Governments and health organizations have ramped up newborn screening programs to ensure early intervention, leading to improved patient outcomes and reduced healthcare costs. Additionally, the expansion of premarital and prenatal screening initiatives has further reinforced the need for accessible and accurate testing solutions. As awareness of sickle cell disease grows, healthcare systems are integrating advanced screening technologies to facilitate early identification and better treatment planning.

How Are Technological Advancements Improving Sickle Cell Testing? Exploring Innovations in Diagnostic Accuracy and Accessibility

Advancements in diagnostic technology have revolutionized sickle cell anemia testing, enabling more precise, rapid, and cost-effective screening methods. Traditional laboratory tests, such as hemoglobin electrophoresis and high-performance liquid chromatography (HPLC), have been complemented by next-generation diagnostic tools, including point-of-care (POC) testing devices, automated molecular assays, and genetic screening techniques. CRISPR-based gene-editing research has also opened possibilities for identifying genetic mutations associated with sickle cell disease, paving the way for precision medicine approaches. Furthermore, AI-powered diagnostic platforms are enhancing interpretation accuracy, reducing false positives and negatives. The expansion of decentralized testing options, including at-home and community-based screening kits, has made testing more accessible in remote areas with limited healthcare infrastructure. As testing technology continues to evolve, sickle cell anemia diagnostics are becoming more efficient, affordable, and globally accessible.

What Challenges Are Hindering the Adoption of Sickle Cell Testing? Addressing Market Barriers and Healthcare Disparities

Despite the advancements in testing technology, several challenges limit the widespread adoption of sickle cell anemia screening. Limited healthcare infrastructure in low-income regions has hindered the availability of diagnostic tools, restricting access to timely detection and treatment. The high costs associated with molecular and genetic screening methods also pose affordability concerns, making it difficult for underprivileged populations to access quality care. Additionally, inadequate awareness about sickle cell disease and testing options has led to underdiagnosis and delayed interventions, particularly in developing nations. Regulatory hurdles and inconsistent testing guidelines across different regions further complicate market expansion, requiring greater international collaboration to standardize screening programs. Addressing these challenges will require targeted investments in healthcare infrastructure, policy reforms, and public health campaigns to increase accessibility and awareness.

What’s Driving the Growth of the Sickle Cell Anemia Testing Market? Identifying Key Expansion Trends and Healthcare Initiatives

The growth in the sickle cell anemia testing and screening market is driven by several factors, including government-backed screening programs, advancements in molecular diagnostics, and increased healthcare funding. National newborn screening mandates have played a crucial role in expanding early detection efforts, prompting investments in advanced diagnostic technologies. The rising prevalence of sickle cell disease in developing countries has further accelerated the demand for affordable and scalable screening solutions. Additionally, global health organizations and non-profit initiatives are funding research and community-based programs to enhance disease awareness and testing accessibility. The expansion of genetic testing services and CRISPR-based innovations has also contributed to market growth, as personalized medicine approaches gain traction in managing sickle cell disease. With ongoing advancements in diagnostics and increasing global efforts to improve disease management, the market for sickle cell anemia testing is expected to witness sustained growth, improving patient outcomes worldwide.

SCOPE OF STUDY:

The report analyzes the Sickle Cell Anemia Testing and Screening market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Technology (Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests, Other Tests); Age Group (Below 1 yr, 25 - 60 yrs, Others); Sector Type (Government Labs, Private Labs, Corporate Labs, PPP)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 32 Featured) -

• Alpha Laboratories
• ASI (Analytical Services International)
• Atlas Medical
• Beam Therapeutics
• BioMedomics Inc.
• Bio-Rad Laboratories, Inc
• bluebird bio Inc.
• Bristol-Myers Squibb Company
• Cigna
• CRISPR Therapeutics
• Daktari Diagnostics
• Emmaus Life Sciences, Inc.
• Fisher Scientific
• Functional Fluidics
• Global Blood Therapeutics, Inc. (Pfizer Inc.)
• Hemex Health
• HEMEX HEALTH
• HemoTypeSC
• Imara Inc.
• KovaDx
• Laboratory Corporation of America Holdings
• LABS Inc.
• Mayo Clinic
• Modus Therapeutics
• Novartis AG
• Pfizer Inc.
• Quest Diagnostics
• Sanofi SA
• Silver Lake Research Corporation
• STRECK, INC

AI INTEGRATIONS
We`re transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR
Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.